

Table e-1. Number of participants with possible or definite primary age-related tauopathy at autopsy

Classification	Global CDR <sup>a</sup>	CERAD semiquantitative neuritic plaque score	Braak stage						total
			0	I	II	III	IV	V	
PART, definite	0	none	8	18	21	15	10	0	0
	0.5	none	5	5	11	4	11	2	1
	1	none	2	6	7	4	6	0	3
	2	none	1	5	3	8	2	0	0
	3	none	4	0	3	2	2	1	0
Amyloid sparse	0	sparse	1	8	14	8	9	1	1
	0.5	sparse	1	5	8	15	17	1	5
	1	sparse	2	2	6	4	15	2	1
	2	sparse	0	2	6	3	10	10	10
	3	sparse	0	1	2	3	7	6	21

Abbreviations: PART = primary age-related tauopathy; CDR = clinical dementia rating; CERAD = Consortium to Establish a Registry for Alzheimer's Disease

<sup>a</sup>CDR at last visit before death, within 1 year of autopsy

Table e-2. Adjusted odds of symptomatic primary age-related tauopathy (definite and possible combined), including Braak stage 0-VI

Test	Adjusted analysis		
	OR	95% CI	p-value
Age at last visit (years)	0.99	0.95-1.04	0.77
Education (years)	0.93	0.86-1.01	0.08
<i>APOE</i> (at least one ε4 vs no ε4 allele)	1.80	0.75-4.36	0.19
Depression	<b>3.66</b>	<b>2.10-6.38</b>	<b>&lt;.0001</b>
History of stroke (yes vs no)	<b>3.68</b>	<b>1.82-7.44</b>	<b>0.0003</b>
History of diabetes (yes vs no)	0.67	0.29-1.56	0.36
Braak stage (0 through VI)	<b>1.60</b>	<b>1.32-1.94</b>	<b>&lt;.0001</b>
Diffuse plaques (any vs none)	0.99	0.57-1.70	0.96
Microinfarct (yes vs no)	1.48	0.87-2.52	0.15
Amyloid angiopathy	1.94	0.98-3.83	0.06

Abbreviations: PART= primary age-related tauopathy; OR = odds ratio; CI = confidence interval; *APOE* = apolipoprotein E

Table e-3. Adjusted odds of symptomatic primary age-related tauopathy, including Braak stage 0-VI but restricted to those with no hippocampal sclerosis

Test	PART, definite			Amyloid sparse		
	OR	95% CI	p-value	OR	95% CI	p-value
Age at last visit (years)	0.96	0.92-1.00	0.05	1.08	1.00-1.16	0.06
Education (years)	1.03	0.90-1.19	0.64	<b>0.81</b>	<b>0.67-0.98</b>	<b>0.03</b>
APOE (at least one ε4 vs no ε4 allele)	3.04	0.98-9.38	0.05	2.73	0.36-20.65	0.33
Depression	<b>3.59</b>	<b>1.73-7.45</b>	<b>0.0006</b>	6.87	0.38-124.91	0.19
History of stroke (yes vs no)	<b>9.62</b>	<b>2.63-35.23</b>	<b>0.0006</b>	1.32	0.41-4.27	0.64
History of diabetes (yes vs no)	0.42	0.12-1.53	0.19	3.37	0.55-20.47	0.19
Braak stage 0 through 6	<b>1.52</b>	<b>1.07-2.15</b>	<b>0.02</b>	<b>2.00</b>	<b>1.10-3.64</b>	<b>0.02</b>
Diffuse plaques (yes vs no)	0.48	0.19-1.19	0.11	0.24	0.01-5.12	0.36
Microinfarct (yes vs no)	1.28	0.57-2.86	0.55	1.49	0.51-4.36	0.46
Amyloid angiopathy	1.18	0.40-3.44	0.76	<b>3.41</b>	<b>1.43-8.12</b>	<b>0.006</b>

Abbreviations: PART= primary age-related tauopathy; OR = odds ratio; CI = confidence interval; APOE = apolipoprotein E

Table e-4. Adjusted odds of symptomatic primary age-related tauopathy (definite and possible combined), excluding Braak stage V-VI

Test	Adjusted analysis		
	OR	95% CI	p-value
Age at last visit (years)	1.00	0.96-1.04	0.97
Education (years)	<b>0.92</b>	<b>0.85-1.00</b>	<b>0.04</b>
<i>APOE</i> (at least one ε4 vs no ε4 allele)	1.63	0.70-3.80	0.26
Depression	<b>3.72</b>	<b>2.09-6.63</b>	<b>&lt;.0001</b>
History of stroke	<b>3.54</b>	<b>1.77-7.07</b>	<b>0.0003</b>
History of diabetes (yes vs no)	0.71	0.30-1.68	0.43
Braak stage (0 through VI)	<b>1.40</b>	<b>1.13-1.72</b>	<b>0.002</b>
Diffuse plaques (any vs none)	1.09	0.64-1.87	0.74
Microinfarct (yes vs no)	1.41	0.87-2.29	0.17
Amyloid angiopathy	1.71	0.91-3.21	0.10

Abbreviations: PART= primary age-related tauopathy; OR = odds ratio; CI = confidence interval; *APOE* = apolipoprotein E

Table e-5. Adjusted odds of symptomatic (clinical diagnosis of cognitive impairment) primary age-related tauopathy, including Braak stage 0-VI

Test	PART, definite			Amyloid sparse		
	OR	95% CI	p-value	OR	95% CI	p-value
Age at last visit (years)	<b>0.96</b>	<b>0.93-1.00</b>	<b>0.04</b>	1.06	0.99-1.15	0.11
Education (years)	1.03	0.91-1.15	0.67	<b>0.80</b>	<b>0.66-0.96</b>	<b>0.02</b>
<i>APOE</i> (at least one ε4 vs no ε4 allele)	2.14	0.91-5.01	0.08	2.77	0.55-13.95	0.22
Depression	<b>3.54</b>	<b>2.03-6.17</b>	<b>&lt;0.0001</b>	5.34	0.69-41.29	0.11
History of stroke (yes vs no)	<b>7.63</b>	<b>2.81-20.77</b>	<b>&lt;0.0001</b>	1.02	0.39-2.68	0.97
History of diabetes (yes vs no)	0.55	0.16-1.92	0.35	1.47	0.33-6.50	0.61
Braak stage 0 through 6	1.30	0.94-1.81	0.11	<b>1.90</b>	<b>1.07-3.37</b>	<b>0.03</b>
Diffuse plaques (yes vs no)	0.53	0.24-1.15	0.11	0.29	0.02-4.34	0.37
Microinfarct (yes vs no)	1.42	0.59-3.46	0.43	1.06	0.44-2.59	0.89
Amyloid angiopathy	1.69	0.67-4.27	0.27	<b>3.13</b>	<b>1.43-6.83</b>	<b>0.004</b>

Abbreviations: PART= primary age-related tauopathy; OR = odds ratio; CI = confidence interval; *APOE* = apolipoprotein E

Table e-6. Adjusted odds of symptomatic primary age-related tauopathy, including previously excluded comorbidities as covariates

Test	PART, definite			Amyloid sparse		
	OR	95% CI	p-value	OR	95% CI	p-value
Age at last visit (years)	0.98	0.95-1.02	0.39	1.05	1.00-1.11	0.05
Education (years)	1.02	0.93-1.11	0.70	0.89	0.75-1.05	0.18
Male sex	1.97	0.87-4.47	0.11	<b>2.29</b>	<b>1.19-4.43</b>	<b>0.02</b>
<i>APOE</i> (at least one ε4 vs no ε4 allele)	1.70	0.86-3.38	0.13	2.09	0.49-8.93	0.32
Depression	<b>3.15</b>	<b>1.71-5.82</b>	<b>0.0002</b>	<b>9.40</b>	<b>1.28-68.80</b>	<b>0.03</b>
History of hypertension (yes vs no)	0.62	0.30-1.29	0.20	0.49	0.17-1.37	0.17
Family history of cognitive impairment (yes vs no)	1.23	0.62-2.43	0.55	1.10	0.58-2.08	0.78
History of diabetes (yes vs no)	0.62	0.36-1.08	0.09	0.65	0.24-1.81	0.41
Braak stage 0 through 6	<b>1.42</b>	<b>1.08-1.87</b>	<b>0.01</b>	<b>1.60</b>	<b>1.19-2.15</b>	<b>0.002</b>
Diffuse plaques (yes vs no)	0.52	0.26-1.05	0.07	0.59	0.06-6.00	0.66
Tau pathologies	<b>26.90</b>	<b>2.99-241.87</b>	<b>0.003</b>	NA	NA	NA
Other neurodegenerative disease	<b>21.48</b>	<b>3.23-142.67</b>	<b>0.002</b>	<b>13.54</b>	<b>1.62-113.34</b>	<b>0.02</b>
Lewy body disease	1.91	0.78-4.71	0.16	<b>4.64</b>	<b>1.34-16.07</b>	<b>0.02</b>

Abbreviations: PART= primary age-related tauopathy; OR = odds ratio; CI = confidence interval; *APOE* = apolipoprotein E; NA = Not applicable